Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + HIPEC + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
ICI-HIPET is a combination therapeutic regimen being investigated for the treatment of advanced ovarian cancer (Stage IIIc-IVA). The protocol consists of the immune checkpoint inhibitor tislelizumab (an anti-PD-1 monoclonal antibody) administered in conjunction with hyperthermic intraperitoneal chemotherapy (HIPEC) and standard systemic chemotherapy comprising paclitaxel and carboplatin. The regimen is designed to leverage the potential of HIPEC to modulate the tumor microenvironment by reducing immunosuppressive cells and enhancing the sensitivity of the tumor to immunotherapy. This specific protocol is being evaluated in a Phase 2 clinical trial led by investigator Jing Li to improve outcomes in patients with high-grade serous ovarian cancer.
- Other names
- ICI-HIPET-Jing Li-ovarian cancerHIPEC + Tislelizumab in Advanced Ovarian Cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on tislelizumab + HIPEC + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + HIPEC + paclitaxel + carboplatin.